Efficient transduction with recombinant adenovirus in EBV-transformed B lymphoblastoid cell lines. 2004

Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
Department of Microbiology and Immunology, Clinical Institute of St. Mary's Hospital, The Catholic University of Korea, Seoul 131-701, Korea.

The Epstein-Barr-transformed B lymphoblastoid cell lines, LCL, which express antigens, are potential antigen-presenting cells (APCs) for the induction of cytotoxic T lymphocytes in vitro. However, transfecting LCL with subsequent selection by antibiotics is notoriously difficult because the plating efficiencies of LCL are reported to be 1% or less. Therefore, this study investigated the optimal conditions for increasing the transduction efficiency of a recombinant adenovirus to LCL for use as a source of APCs. The transduction efficiencies were < 13% (SD +/- 2.13) at a multiplicity of infection (MOI) of 100, while it was increased to 28% (SD +/- 9.43) at an MOI of 1000. Moreover, its efficiencies to LCL that expressed the coxsackie adenovirus receptor were increased to 60% (SD +/- 6.35) at an MOI of 1000, and were further increased to 70% (SD +/- 4.56) when combined with the centrifugal method. The cationic liposome or anionic polymer had no effect on the transduction efficiency when compared to that of the centrifugal method. These results may be used as a convenient source of target cells for a CTL assay and/or autologous APCs for the induction of the in vitro CTL responses that are specific to viral and tumor antigens.

UI MeSH Term Description Entries
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D002472 Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus. Transformation, Viral Cell,Viral Cell Transformation,Cell Transformations, Viral,Transformations, Viral Cell,Viral Cell Transformations
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000256 Adenoviridae A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. Adenoviruses,Ichtadenovirus,Adenovirus,Ichtadenoviruses
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D014161 Transduction, Genetic The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE. Genetic Transduction,Genetic Transductions,Transductions, Genetic

Related Publications

Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
January 2004, Biochimica et biophysica acta,
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
January 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
February 1996, Thyroid : official journal of the American Thyroid Association,
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
January 1985, Chromosoma,
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
July 1984, Science (New York, N.Y.),
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
March 1987, International journal of cancer,
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
June 2000, Journal of immunology (Baltimore, Md. : 1950),
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
July 2013, Cancer immunology, immunotherapy : CII,
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
May 2001, Current protocols in immunology,
Hye-Jin Kim, and Hyun-Il Cho, and Yoon-Hee Han, and Soo-Young Park, and Dong-Wook Kim, and Dong-Gun Lee, and Jee-Hoon Kim, and Wan-Shik Shin, and Soon-Young Paik, and Chun-Choo Kim, and Young-Seon Hong, and Tai-Gyu Kim
February 2011, Cell proliferation,
Copied contents to your clipboard!